Overview

Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing the degree of early allograft liver dysfunction, as assessed by postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), during first 7 postoperative days and by serum and histochemical markers of liver injury and inflammation.
Phase:
N/A
Details
Lead Sponsor:
Republican Scientific and Practical Center for Organ and Tissue Transplantation
Treatments:
Tacrolimus